

---

## Meet MIAC's new Scientific Advisory Board

Today we're unveiling our new Scientific Advisory Board (SAB), which brings together four leading experts who are making significant contributions to the exciting field of neuroscience and pushing its boundaries. Our SAB is a multi-disciplinary panel with advanced knowledge in research, providing medical consulting for our clinical trials in multiple sclerosis, NMOSD, dementia, stroke and Alzheimer's disease. Additionally, expertise in translational molecular neuroimaging and PET-related inquiries is provided.

*"The establishment of our Scientific Advisory Board marks a significant milestone for MIAC. It underscores our commitment to innovation and development as a leading imaging CRO specializing in neurodegenerative, neuroinflammatory, and cerebrovascular diseases.*

*Individually, each member of the SAB brings world-class expertise in areas at the forefront of neuroscience, from novel imaging technologies to pathophysiological research to clinical trials. We believe that the insight and guidance provided by our board members will be instrumental in helping us achieve our goals and taking us to the next level in advancing medical imaging and driving improved patient outcomes."* our co-CEOs Marika Grunze and Marco Düring explained.

*Meet our SAB members:*



**Prof. Cristina Granziera**, a highly accomplished clinical researcher, is a leading authority in neurology and neuroimaging. She focuses on innovative neuroimaging methods to understand brain and spinal cord changes in multiple sclerosis patients. Her groundbreaking research, validated in large clinical trials, has transformed the treatment and care of MS patients.

In 2011, she was appointed as a lecturer at the University of Lausanne, where she was promoted to senior lecturer in 2014. In 2015, she joined the Massachusetts General Hospital (MGH) and Harvard Medical School (Boston, MA, USA) as an assistant professor in Radiology and assistant in Biomedical Engineering. Currently, she works as a senior consultant neurologist at the University Hospital of Basel, as a professor in neurology and biomedical engineering at the University of Basel, and as co-CEO of the "Research Center for Neuroscience and Neuroimmunology (RC2NB)" in Basel.



**Dr. Ruth Galdes** is a neurologist with a special interest in inflammatory disorders of the central nervous system (CNS) especially multiple sclerosis and NMOSD. She is currently the Lead for the MS trials Unit and the Deputy Lead for the National Highly Specialized service for NMO at the Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK. She is also the Lead for the MS service at Frimley Health Foundation Trust and the KSS NIHR lead for Neurology and Neurodegeneration. She trained at Santa Maria University Hospital in Lisbon, Portugal. Her DPhil project at Oxford University explored the relationship between vascular disease and MS through the examination of post-mortem and brain MRI studies. Her current work aims to better understand the effect of environmental factors on clinical/Imaging outcomes in MS and NMOSD, contrasting clinical and imaging features between inflammatory conditions of the CNS and identify the best strategies to provide holistic treatment/care to people with these disorders.



**Prof. Steven Greenberg**, a distinguished neurology professor at Harvard Medical School, holds prestigious positions including the John J. Conway Endowed Chair in Neurology and Vice-Chair for Faculty Development and Promotions at Massachusetts General Hospital. As the director of the renowned Hemorrhagic Stroke Research Program, his expertise in cerebral amyloid angiopathy has gained international recognition. With an extensive publication record and leadership roles in various national and international initiatives, Steven Greenberg has made significant contributions to the fields of hemorrhagic stroke, small vessel brain disease, and related neurological conditions. Steven Greenberg is Principal Investigator for the coordinating center of the NIH-funded multi center MarkVCID consortium to validate biomarkers for small vessel diseases associated with cognitive impairment and dementia.



**Prof. Dr. Matthias Brendel** leads the molecular imaging group for neurodegenerative diseases at the Ludwig-Maximilians Universität München. His research focuses on translational molecular neuroimaging using PET to understand the connections between protein aggregation and neuroinflammation in neurodegenerative disorders. As a Principal Investigator and co-Investigator, Matthias Brendel has successfully managed university-funded projects, collaborated extensively, and produced numerous peer-reviewed publications. From his doctoral thesis onwards, he has contributed to groundbreaking preclinical studies, including the first methodological evaluations of amyloid PET in dedicated small models. Matthias Brendel also has a notable track record in coordinating academic research, highlighted by his recent involvement in a multi-center study on second-generation tau-PET in progressive supranuclear palsy.

The MIAC team is truly excited about the opportunities that lie ahead with our Scientific Advisory Board. We are confident that their collective knowledge and expertise will foster innovation, enrich our research capabilities, and ultimately make a meaningful impact in the field of neurosciences.